Search results
Showing 271 to 285 of 1259 results for pathway
QuickChange Incontinence Wrap for urinary incontinence in men (MIB237)
NICE has developed a medtech innovation briefing (MIB) on QuickChange Incontinence Wrap for urinary incontinence in men .
TYM smartphone otoscope for imaging and videoing the external ear canal and eardrum (MIB134)
NICE has developed a medtech innovation briefing (MIB) on the TYM smartphone otoscope for imaging and videoing the external ear canal and eardrum .
Dupilumab for treating moderate to severe atopic dermatitis (TA534)
Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults.
Evidence-based recommendations on leniolisib (Joenja) for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over.
GaitSmart rehabilitation exercise programme for gait and mobility issues (HTG716)
Evidence-based recommendations on GaitSmart rehabilitation exercise programme for gait and mobility issues in adults.
NICE has developed a medtech innovation briefing (MIB) on Bindex for investigating suspected osteoporosis .
Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)
Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis in adults.
NICE has developed a medtech innovation briefing (MIB) on OxyMask for delivering oxygen therapy .
Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver.
NICE has reviewed DMD Care UK’s guideline on cardiac care of children with dystrophinopathy and females carrying DMD-gene variations. We think the guideline from DMD Care UK is a useful resource that will help clinicians improve care in this area
This quality standard covers care after emergency treatment for suspected anaphylaxis, including assessment and referral to specialist allergy services. It describes high-quality care in priority areas for improvement.
View quality statements for QS119Show all sections
Sections for QS119
- Quality statements
- Quality statement 1: Initial education in adrenaline auto-injector use
- Quality statement 2: Referral to specialist allergy services after emergency treatment
- Quality statement 3: Specialist assessment for venom immunotherapy
- Quality statement 4: Ongoing training in adrenaline auto-injector use
- Update information
- About this quality standard
Urethrotech UCD for difficult or failed catheterisation (MIB116)
NICE has developed a medtech innovation briefing (MIB) on the Urethrotech UCD for difficult or failed catheterisation .
Cardiovascular risk assessment and lipid modification (QS100)
This quality standard covers identifying and assessing cardiovascular risk in adults without cardiovascular disease, and treatment to prevent primary and secondary cardiovascular disease. It describes high-quality care in priority areas for improvement.
View quality statements for QS100Show all sections
Sections for QS100
- Quality statements
- Quality statement 1: Identifying adults who are likely to be at high risk
- Quality statement 2: Diet and lifestyle advice for primary prevention
- Quality statement 3: Lipid-lowering treatment for primary prevention
- Quality statement 4: Assessing response to lipid-lowering treatment
- Quality statement 5: Secondary prevention of cardiovascular disease
- Update information
- About this quality standard
Faricimab for treating wet age-related macular degeneration (TA800)
Evidence-based recommendations on faricimab (Vabysmo) for wet age-related macular degeneration in adults.
NICE has developed a medtech innovation briefing (MIB) on PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes .